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Background: The indocyanine green dilution method is one of the methods
available to estimate plasma volume, although some researchers have questioned
the accuracy of this method.
Methods: We developed a new, physiologically based mathematical model of
indocyanine green kinetics that more accurately represents indocyanine green
kinetics during the first few minutes postinjection than what is assumed when using
the traditional mono-exponential back-extrapolation method. The mathematical
model is used to develop an optimal back-extrapolation method for estimating
plasma volume based on simulated indocyanine green kinetics obtained from the
physiological model.
Results: Results from a clinical study using the indocyanine green dilution method
in 36 subjects with type 2 diabetes indicate that the estimated plasma volumes are
considerably lower when using the traditional back-extrapolation method than when
using the proposed back-extrapolation method (mean (standard deviation) plasma
volume = 26.8 (5.4) mL/kg for the traditional method vs 35.1 (7.0) mL/kg for the
proposed method). The results obtained using the proposed method are more
consistent with previously reported plasma volume values.
Conclusions: Based on the more physiological representation of indocyanine green
kinetics and greater consistency with previously reported plasma volume values, the
new back-extrapolation method is proposed for use when estimating plasma volume
using the indocyanine green dilution method.
Keywords: Clinical pharmacology, Clinical research, Pharmacokinetics and drug
metabolism, Pharmacology, PhysiologyBackground
A method for estimating plasma volume (PV) using indocyanine green (ICG) dilution
was first proposed by Bradley [1]. Following ICG injection, ICG binds to plasma proteins
and is eliminated almost exclusively by the liver [2]. It takes approximately 2 minutes for
ICG concentrations to become well mixed in the plasma, and over the 2- to 5-minute
period following injection, the plasma concentrations of ICG can be well approximated
by a mono-exponential decay [3]. By fitting the measured plasma ICG concentrations
over this time to a mono-exponential decay and using back-extrapolation to obtain the
theoretical initial plasma concentration of ICG (ICG0, defined as the plasma ICG© 2014 Polidori and Rowley; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication
waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise
stated.
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instant mixing of ICG), the PV can be estimated as:
Plasma volume Lð Þ ¼ Dose of ICG administered mgð Þ
Theoretical initial plasma concentration of ICG mg=Lð Þ ð1Þ
Different authors have proposed different back-extrapolation methods to estimate
ICG0 to account for the known properties of ICG removal. In the initial report, Bradley
back-extrapolated to time 0 (the ICG injection time) to obtain ICG0 [1], and this
traditional approach has also been used by others [3-6]. Haneda pointed out that the
traditional approach of back-extrapolating to t = 0 overestimates ICG0 (and therefore
underestimates PV), and they proposed back-extrapolating only to t = ta, which they
defined as the time at which ICG could be measured in the abdominal aorta [2].
Their rationale was that because ICG is excreted primarily by the liver with only
minimal extravasation occurring immediately after injection, there should be almost
no ICG removal from the circulation prior to t = ta. Although measuring the dye concen-
trations in the abdominal aorta is often not practical experimentally, Haneda suggested
that the time it takes ICG to reach the abdominal aorta should be roughly similar to the
time it takes to reach peripheral arteries. In principle, frequent samples could be taken
from a peripheral artery to estimate ta experimentally; however, this approach does not
appear to have been adopted by other researchers.
As an alternative approach to minimize the impact of the time delay associated with
ICG transit from the injection site to the heart and the liver, some researchers have
used a tourniquet prior to ICG injection to produce reactive hyperemia, thereby enabling
more rapid dye mixing in the circulation [5,6].
To better illustrate the potential errors in PV estimation associated with back-
extrapolation, Schröder constructed a physical mixing apparatus and performed several
experiments to estimate the known system volume [7]. Consistent with the theoretical
arguments made by Haneda [2], these experiments demonstrated that back-extrapolating
to t = 0 underestimated the system volume and that the error increased with increasing
clearance in the system. While the Schröder experiments clearly illustrated the errors in
estimating PV associated with back-extrapolation to t = 0, particularly in situations of high
clearance, no alternative back-extrapolation method was proposed.
The purpose of this report is to develop an optimal back-extrapolation method for
estimating PV using ICG, by developing and utilizing a computational fluid dynamics
model of ICG kinetics in human circulation. The computational fluid dynamics model
is simulated over a wide range of ICG clearance values to identify a back-extrapolation
method that yields accurate estimates of PV over the full range of clearance values.
Methods
Mathematical model development
Compartmental models that are commonly used in pharmacokinetic analyses typically
assume perfectly mixed compartments and use ordinary differential equations to describe
the changes in concentrations within each compartment over time. However, because
there is incomplete mixing of ICG in the circulation over the first 2 minutes following
ICG injection and the kinetics of ICG during this time are important for estimating
ICG0, a partial differential equation model describing ICG transit and elimination was
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space and does not assume perfect mixing within a small number of discrete compart-
ments. The physiologically based mathematical model of ICG kinetics was developed
using the following assumptions:
1. ICG is injected into a peripheral vein at t = 0. Prior to t = 0, ICG is not present in
the circulation.
2. Injected ICG is transported to the heart by the blood flow in the vein into which it
was injected.
3. When blood flow from the vein into which ICG was injected reaches the heart, it is
mixed with the blood flow from other vessels and then recirculated to the rest of
the body.
4. Three different circulatory loops were modeled (Figure 1). Within each loop, the
concentration of ICG is calculated at each location and time, and is therefore





regia. Loop 1: Hepatic circulation. This represents 30% of the blood flow, and dye is
extracted (cleared) from blood flowing through this loop. The concentration of
ICG at time t and location x in this loop is denoted by u(t,x) in the equations
below.
b. Loops 2 and 3: Nonhepatic circulation. This represents 70% of the blood
flow, and there is no clearance of ICG from blood traveling in the
nonhepatic circulation. To account for kinetics immediately after injection,
the nonhepatic circulation is broken into 2 different loops. There is no
clearance of ICG from either of these nonhepatic circulatory loops; the
only difference is that ICG is injected directly into 1 of the loops and
not into the other.
1) Loop 2: Nonhepatic circulation, excluding the circulatory loop in which the
dye is injected. This loop represents 65% of total blood flow, and there is no
clearance of ICG from blood flow in this loop. The concentration of ICG in
this loop is denoted by v(t,x). Measurements of circulating ICG
concentrations are taken at x = π in this loop.ure 1 Schematic view of 3-loop blood flow model. Blood flow is divided into 3 circulatory loops, with the
centration in each loop varying in both space (length along the loop) and time. The variables u(t,x), v(t,x), and
x) represent the concentrations of ICG in Loops 1, 2, and 3, as described in the text. In each loop, the spatial
able (x) runs from 0 to 2π, where x = 0 begins in the center (the heart region), x = π is at the opposite end of
circle (eg, where the liver, injection, and measurement sites are illustrated), and x = 2π is back in the center
on. ICG, indocyanine green.
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was modeled to account for 5% of the total blood flow, and there is also no
clearance of ICG in this loop. The concentration of ICG in this loop is
denoted by w(t,x). The ICG injection occurs at x = π and t = 0.5. Within each circulatory loop represented, ICG transit occurs through both
advection (due to blood flow) and diffusion.
Within each circulatory loop, ICG kinetics are modeled using a 1-dimensional advection
diffusion equation; equations of this form are commonly used to model systems in which
particles are transferred within a physical system due to both advection and diffusion [8].
























þ β ⋅ h xð Þ ⋅ m−wð Þ; ð4Þ
where m = ru ⋅ u + rv ⋅ v + rw ⋅w; u(t,x), v(t,x), and w(t,x) are the concentrations of ICG at
time t and location x in each of the 3 loops; c represents the transit rate for blood
through each loop; the ν terms are diffusion coefficients for each loop; α∙f(x) represents
the clearance of ICG from the hepatic circulatory loop; and the β∙h(x) terms represent
mixing in the heart region. For each loop, the spatial variable x goes from 0 to 2π, and
the ICG concentration at x = 0 and x = 2π is the same. The function f(x) specifies the
region within the hepatic loop where clearance takes place (f(x) >0 in a small region
meant to represent the liver and f(x) = 0 elsewhere). The parameter α is used to vary
the magnitude of the hepatic clearance of ICG. Similarly, h(x) >0 in a small region
surrounding x = 0 and x = 2π, meant to represent the heart, and h(x) = 0 elsewhere, and
β is a parameter that can be adjusted to vary the degree of mixing in the heart. The
values of ru, rv, and rw represent the relative blood flows through each loop (ru = 0.3,
rv = 0.65, rw = 0.05), and m represents the mean concentration of ICG in the heart
region.
Additional details describing the parameter values and the initial conditions for the
model are provided in Additional file 1. In brief, the parameter values for the simula-
tions were chosen to be consistent with the following data:
1. Total blood flow is approximately 5 L/min, and total blood volume is approximately 5 L,
so that it takes approximately 1 minute for the blood to circulate through the body [9].
2. Hepatic blood flow is 30% of total blood flow [10].
3. ICG concentrations are well mixed in the plasma by 2 minutes after the injection
time [3]. The values of the diffusion coefficients (ν) and the mixing rate in the heart
(β) were chosen so that simulated concentrations were well mixed by 2 minutes.
4. The plasma ICG decay rate from 2 to 5 minutes postinjection is consistent with
decay rates observed in the clinical study (described below). The parameter
associated with hepatic extraction (α) was varied to cover a range of clearance
values larger than the range observed in the clinical data.
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described [11]. All calculations were performed in Python, version 2.7. The code used
to perform the calculations is included in Additional file 2.Clinical study
Subjects
Eligible subjects were men and women from 25–70 years of age with type 2 diabetes
who were on stable doses of metformin and either an angiotensin-converting enzyme
inhibitor (ACEI) or angiotensin receptor blocker (ARB) and who had an estimated
glomerular filtration rate ≥70 mL/min/1.73 m2. Subjects with conditions or treatments
with potential impact on body fluid were excluded from the study (eg, subjects requiring
treatment with immunosuppressive therapy; subjects with myocardial infarction, pulmon-
ary hypertension, or New York Heart Association Class III-IV heart failure; subjects with
uncontrolled hypertension; subjects taking any antihypertensive medication other than
ACEIs or ARBs; and subjects with chronic gastrointestinal disorders). The study was
conducted at 1 center in Germany. The protocol and amendment were approved by an
Independent Ethics Committee (Ethikkommission der Ärztekammer Nordrhein, Düsseldorf,
Germany). All subjects gave written informed consent, in accordance with the Declaration
of Helsinki, following institutional guidelines, and in compliance with Good Clinical Practice
and regulatory requirements.
Materials
ICG was obtained as a powder from PULSION Medical Systems, Munich, Germany,
and prepared as a 5 mg/mL solution for injection.
Design
This was a randomized, double-blind, placebo-controlled study designed to test the ef-
fects of canagliflozin treatment on PV. Only data from the baseline (pretreatment) visit
are used in this analysis. Prior to the baseline visit, subjects underwent a 2-week,
single-blind, placebo run-in phase and a 3-day diet stabilization period in which sub-
jects received a standardized diet, containing about 200 mEq/day of sodium, while dom-
iciled in the clinical research center. Further details on the study design and subject
inclusion and exclusion criteria can be found in reference [12].
Procedures
During the baseline visit, subjects were given an intravenous bolus injection of ICG
(0.25 mg/kg) over 5 seconds into 1 arm. Blood samples were collected from the other
arm every 30 seconds over the period from 2 to 5 minutes after the ICG injection
(7 samples) [3].
Bioanalytical
Plasma ICG concentrations were determined using a validated high-performance
liquid chromatography (HPLC) analytical method at MLM Medical Labs GmbH,
Dohrweg 63, 41066 Moenchengladbach, Germany. The inter-assay precision was
<7% relative standard deviation, and the accuracy was within ±5% of nominal
concentrations.
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Several simulations of the model equations were performed to mimic the clinical protocol.
In each of the simulations,
1. A specified amount of ICG was injected into Loop 3 at t = 0 into a small region
surrounding x = π.
2. The simulated ICG concentrations were “measured” from a peripheral vein every
30 seconds from t = 2 minutes to t = 5 minutes; the (simulated) measurements were
taken at x = π in Loop 2.
3. The simulated ICG concentrations from t = 2 to 5 minutes were fitted to a
mono-exponential decay by log-transforming the values and using standard
linear regression. The relationship was back-extrapolated to t = 0 to obtain the
traditional PV estimate.
Normalized concentrations were used in the simulations such that a normalized con-
centration of 1 is equal to the dose of ICG injected divided by the total system volume.
Similar to the back-extrapolation to ta proposed by Haneda [2], back-extrapolation to
alternative times was also performed to account for the time delays associated with the
dye traveling to the heart and the liver. The back-extrapolation time that produced the
least error between the known volume in the simulations and the volume estimated
from the back-extrapolation method over a broad range of clearance values was deter-
mined by an iterative search.
Calculated PV for clinical study
For each subject, PV was estimated using both the traditional back-extrapolation
method (back-extrapolating to t = 0) and the proposed optimal back-extrapolation
method. Regression analyses were performed using Matlab, version 8.0.
Results
Simulated ICG concentrations with no ICG clearance
To demonstrate some basic properties of the mathematical model, initial simulations
were performed with no ICG clearance (α = 0). In this case, the total amount of ICG in
the 3 loops remains constant over time. Figure 2A shows the average ICG concentration
within each of the circulatory loops at each time point, where the average concentration
in a loop is defined as the spatial average along the length of each loop; for example, the
average concentration in the hepatic circulation loop is given by:




u t; xð Þdx ð5Þ
The curve labeled “average concentration” shows the average ICG concentration in the
entire system, which is equal to the total amount of ICG in the 3 loops divided by the sum
of the total volume in each loop. As expected, this “average concentration” remains con-
stant over time because there is no clearance. The time delays between ICG injection at
t = 0 and the rise in the various concentrations shown in Figure 2A are due to the time de-
lays associated with dye transit from the injection site to the heart and the liver. After a
Figure 2 ICG concentrations for model simulations with no ICG clearance (α = 0) and with hepatic
ICG clearance. Note: For panel A (with no ICG clearance), concentrations are normalized so that a value of
1 is equal to the injected dose of ICG divided by the total system volume; for simulations in panel B
(with hepatic ICG clearance), α = 27. ICG, indocyanine green.
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trations at any site in the circulation are approximately equal to the average concentration.
Simulated ICG concentrations with hepatic ICG clearance
A representative ICG kinetic response when hepatic ICG clearance (as described in
Additional file 1) is added to the model is shown in Figure 2B. As in the simulations
performed with no clearance, a time delay appears between the ICG injection at t = 0
and the rise in ICG concentrations in the hepatic and nonhepatic circulatory loops.
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culatory loops due to ICG clearance in the hepatic circulatory loop. The average con-
centration for the entire system volume remains at 1 until the injected dye first reaches
the liver (at around t = 0.7 minutes) and then falls exponentially after that.
Note that the average ICG concentration in the nonhepatic circulatory loop is always
higher than the average ICG concentration in the hepatic circulatory loop due to ICG
clearance in the hepatic loop. Therefore, after the initial mixing period, the average
ICG concentration in the noncirculatory loop where blood samples are taken is
always modestly higher than the average ICG concentration throughout the entire
system volume. The difference between the average concentration of ICG in the non-
hepatic circulatory loop (ie, v tð ÞÞ and the overall average concentration increases
with increasing amounts of hepatic ICG extraction. This point is discussed further
when the sources of error associated with the standard back-extrapolation method
are summarized.
Figure 3 illustrates the impact of different clearance rates on the estimated theoretical
ICG0 values obtained by back-extrapolation and is similar to the results obtained in the
physical experiments performed by Schröder [7]. For the 2 different clearance values
shown (α = 1 and α = 10), equations 2, 3, 4 and 5 were solved to obtain the simulated
measured ICG concentrations (ie, v(t,π)) over the period t = 2 to 5 minutes. These
“measured” concentrations were then fit to a single exponential decay, as in reference
3, and the exponential functions were back-extrapolated to t = 0 to obtain the estimated
ICG0 values. In both cases shown, the true value of ICG0 = 1. When ICG clearance was
low, there was very little error in the estimated ICG0 value; but for the higher clearance
case, the back-extrapolated ICG0 value was approximately 20% higher than the true
value of 1. Note that because PV is calculated as Dose/ICG0, a 20% overestimation of
ICG0 will lead to a 17% underestimation of PV.Figure 3 Illustration of the back-extrapolation method for 2 different clearance rates. Note: The
back-extrapolation for each case was performed by fitting the simulated data from t = 2 to 5 minutes to a
mono-exponential decay and then back-extrapolating to t = 0 [3].
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As shown in Figure 3, back-extrapolation to t = 0 overestimates ICG0 (and therefore
underestimates PV) when there is hepatic ICG extraction. This is further illustrated in
Figure 4A, where the error in the estimated PV is shown as a function of the clearance
rate. When back-extrapolating to t = 0, the errors in the estimated PV increase withA
B
Figure 4 Errors in estimating plasma volume by back-extrapolation for different clearance rates and
different back-extrapolation times. In panel A, the ratio of the estimated PV to the true PV is shown for
a range of ICG clearance in the simulations for two different back-extrapolation times (t = 0 and t = 1.08
min). Note that low values of α correspond to low clearance rates and, for values of α >100, there is nearly
complete extraction of ICG by the liver. In panel B, the percentage error is the estimated PV is shown as a
function of the back-extrapolation time used for simulations performed with clearance parameter α = 29
(for this value of α, the simulated plasma ICG profile is similar to the mean plasma ICG profile observed in
the clinical study [12]). PV, plasma volume; ICG, indocyanine green.
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for high hepatic ICG extraction rates. These simulation results are consistent with
the experimental results obtained with the physical mixing apparatus developed by
Schröder [7].
There are 2 reasons why back-extrapolating to t = 0 overestimates ICG0 and therefore
underestimates PV:
1. There is a time delay associated with injected dye traveling to the heart and then to the
liver. During this period, there is no hepatic ICG extraction, but the back-extrapolation
to t = 0 method assumes that the circulating ICG follows the same exponential decay
rate beginning at t = 0 as it does when it is well mixed in the circulation.
2. As illustrated in Figure 2B, the ICG concentration in the nonhepatic circulatory
loop (where blood samples are taken for measuring ICG) is higher than the ICG
concentration would be if it was perfectly mixed throughout the entire PV. This is
because the ICG concentration in the posthepatic portion of the hepatic circulatory
loop is much lower than the ICG concentration in the rest of the circulation.
The magnitude of the error associated with each of these sources of error increases
with increasing ICG clearance.
As a result of these errors, alternative back-extrapolation schemes were tested in the
simulations. Based on the work of Haneda [2], in which back-extrapolation was done
only to the time at which ICG was measured in the abdominal aorta, the following
analyses were performed:
1. Model simulations of ICG concentrations in the different circulatory loops were
performed over the range of clearance values shown in Figure 4A.
2. In each simulation, measurements taken over the period t = 2 to 5 minutes were
used to obtain a mono-exponential fit.
3. The exponential fit was back-extrapolated to different time values (denoted as t = ta)
to estimate the theoretical initial concentration of ICG (assuming perfect mixing)
and then calculate the PV (as Dose/ICG(t = ta)). The calculated PV obtained by the
different back-extrapolation methods was compared to the true system volume.
4. The value of ta that produced the least error over the full range of clearance values
was determined by an iterative search.
For the simulations performed, the optimal value of ta was found to be 1.08 minutes.
As shown in Figure 4A, by back-extrapolating to ta = 1.08 minutes and using ICG(t = ta)
when calculating PV, there was virtually no error in the estimated PV over the full
range of simulated ICG clearance values.
Note that the optimal value for ta is dependent on several parameters chosen in the
simulations, including:
1. The location in the nonhepatic circulatory loop where the dye is injected,
2. The location of the liver in the hepatic circulatory loop,
3. The location where blood samples are taken from the nonhepatic circulatory loop, and
4. The flow rates in the circulatory loops.
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the circulatory loops (x = π), and the flow rate in the circulatory loops (circulating once
per minute) was consistent with the commonly quoted values of blood flow and blood
volume. However, as there is some uncertainty (and likely individual variability) associated
with each of these assumptions, a sensitivity analysis was performed to assess how
sensitive the estimated PV is to the assumed ta value. This was done by using the
simulated results described earlier for a specific case of α = 29 (chosen so that the
ICG decay rate in the simulations is similar to decay rates observed in the clinical
data) and estimating PV for different back-extrapolation times ta. As described earlier,
when ta = 0, PV is underestimated by a considerable amount, and when ta = 1.08 minutes,
there is virtually no error (Figure 4B). As shown in Figure 4B, as long as ta is between
0.7 and 1.4 minutes, there is less than a 10% error in the estimated PV obtained by the
back-extrapolation method. Thus, although the true optimal value of ta will be some-
what uncertain and variable due to the transit times associated with the circulatory
flow rates and distances from the injection site to the heart, the liver, and the site of
blood samples for measuring ICG, relatively small errors for PV are obtained over a
range of ta values.
Based on the simulations performed and the existing uncertainties, it is proposed that
a time of ta = 1 minute be used in the back-extrapolation method.Clinical study: subject characteristics
Thirty-six subjects were studied. All subjects studied were white, and 31 were male.
Demographic and baseline disease characteristics for the subjects are presented in
Table 1.Estimated PV from the clinical study
Individual subject data obtained from the clinical study were used to compare the PV
estimates obtained by 2 different back-extrapolation methods. For each subject, the
logarithms of the measured ICG values obtained from t = 2 to 5 minutes were calcu-
lated, and standard linear regression was used to determine the decay rate. The linear
regression relationship provided a good fit to the data in all of the subjects (r2 for
individual subjects ranged from 0.937–0.998; a figure showing the mean data is pro-
vided in Additional file 3: Figure S3). The regression relationship was then used
to determine PV by back-extrapolating the regression relationship to either t = 0 orTable 1 Demographic and baseline disease characteristics
Measure Mean (SD) Median (range)
Age (years) 63 (6) 63 (51–71)
Body weight (kg) 94 (14) 88 (73–130)
Height (cm) 176 (9) 176 (155–192)
BMI (kg/m2) 30 (3) 30 (24–37)
HbA1c (%) 7.7 (0.5) 7.7 (7–9)
eGFR (mL/min/1.73 m2) 97 (16) 100 (71–132)
Duration of diabetes (years) 9 (4) 8 (2–18)
SD standard deviation, BMI body mass index, HbA1c hemoglobin A1c, eGFR estimated glomerular filtration rate.
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methods are shown in Table 2.
The PV estimates obtained when back-extrapolating to t = 0 are below commonly
reported PV values of approximately 3 L or approximately 40 mL/kg [13,14], consistent
with the results from the simulations and Schröder’s physical experiments showing that
back-extrapolation to t = 0 underestimates PV [7]. In contrast, the estimated PVs
obtained by back-extrapolating to t = 1 minute are more consistent with commonly
reported PV values, particularly when considering that the average body weight of the
subjects in the study (94 kg) is higher than the reference 70-kg man for which the 3-L
value of PV is commonly quoted.Discussion
Several research groups have estimated PV using ICG injections in humans. Following
injection, ICG is rapidly bound to plasma proteins and is removed almost exclusively
by the liver. Jacob and colleagues utilized a single-compartment model of ICG kinetics
over the period from 2 to 5 minutes postinjection to fit the plasma ICG profile using a
mono-exponential decay, and then back-extrapolated the exponential function to t = 0
to estimate ICG0 and PV [3]. However, several researchers have noted that the traditional
approach of back-extrapolating to t = 0 will tend to underestimate PV, largely due to
incomplete ICG mixing over the first 2 minutes postinjection and the time lag asso-
ciated with ICG transit from the injection site to the heart and the liver, where it is
extracted [2,7].
Various alternative methods have been proposed to estimate PV, including back-
extrapolating only to a time ta >0, where ICG concentrations could first be measured in
the abdominal aorta [2] or using a tourniquet prior to ICG injection to produce reactive
hyperemia and speed the mixing of ICG in the circulation [5,6]. In order to better
characterize the errors associated with the traditional back-extrapolation method and to
develop an improved methodology, a mathematical model of ICG kinetics was developed
and simulations were performed to identify a back-extrapolation method that would pro-
vide minimal errors in the estimated PV over a wide range of ICG clearance values.
The form of the mathematical model used in the analysis (advection diffusion equa-
tions) is commonly used to describe physical systems in which particles are transferred by
both convection and diffusion, and is appropriate for modeling ICG kinetics. Simulations
were performed to cover a broad range of hepatic ICG clearance rates and, consistent
with the physical experiments performed by Schröder [7], the errors in the estimated
ICG0 values obtained when back-extrapolating to t = 0 increased with increasing clearance
rates. This result makes intuitive sense, as back-extrapolating to t = 0 assumes that theTable 2 Mean (SD) estimates for PV in subjects with type 2 diabetes studied prior to
treatment
Back-extrapolation time N PV (L) PV (mL/kg)
t = 0 36 2.5 (0.6) 26.8 (5.4)
t = 1 minute 36 3.3 (0.8) 35.1 (7.0)
SD standard deviation, PV plasma volume, ICG indocyanine green.
Note: For each subject, PV was estimated using standard linear regression of the log-transformed ICG concentrations and
back-extrapolation to the specified time point for estimation of the theoretical initial concentration of ICG.
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liver) as when the dye is well mixed in the circulation over the 2- to 5-minute period; the
errors associated with this assumption will be higher in cases of high clearance. Based on
the work of Haneda [2], alternative back-extrapolation times were tested, and it was
demonstrated that if ICG concentrations are back-extrapolated to t = 1 minute rather
than to t = 0, only minimal errors in the estimated ICG0 (and hence in the estimated
PVs) are obtained over a broad range of clearance values.
While the analyses described here provide a practical, model-based method for improv-
ing the accuracy of ICG-based estimates of PV, there are some limitations associated with
the analyses. The parameter estimates used in the model simulations were based on previ-
ously reported mean values rather than being estimated at an individual subject level. In
addition, while the simulations covered a broad range of clearance values, the impact of
variability in cardiac output and peripheral blood flow distribution [15,16] was not consid-
ered in the analyses. Finally, no study was done to directly compare PV estimated using
ICG dilution and the proposed back-extrapolation method with PV estimated using a
“gold standard” method like 125I-albumin [17]. Although these limitations represent areas
of potential future work, they are not believed to alter the primary conclusion of this
paper that the proposed back-extrapolation scheme is expected to yield more accurate
estimates of PV than the traditional back-extrapolation method.Conclusions
In summary, based on the analyses performed, the ICG dilution method for estimating PV
using the plasma sampling described by Jacob [3] will likely yield more accurate estimates
of PV when the theoretical initial ICG concentration is estimated using back-extrapolation
to t = 1 minute rather than the traditional approach of back-extrapolating to t = 0.
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